Bardoxolone methyl

Drug Profile

Bardoxolone methyl

Alternative Names: Bard - Reata Pharmaceuticals; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Kyowa Hakko Kirin; Reata Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules; Triterpenes
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary arterial hypertension
  • Phase II/III Hereditary nephritis
  • Phase II Diabetic nephropathies
  • Discontinued Haematological malignancies; Malignant melanoma; Non-alcoholic steatohepatitis; Pancreatic cancer; Solid tumours; Viral hepatitis

Most Recent Events

  • 01 Feb 2017 Phase-II/III clinical trials in Hereditary nephritis in USA (PO) (NCT03019185)
  • 14 Nov 2016 Reata plans a phase II/III trial for Hereditary nephritis (Alport syndrome) in USA
  • 11 Nov 2016 Efficacy and adverse events data from an open label extension study of the phase II LARIAT study in Pulmonary arterial hypertension presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top